Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2017
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Tokyo Stock Exchange containing financial results for the quarter ended September 30, 2017, and a full-year forecast for 2017. This filing serves as Regulation FD disclosure.
Key Financial Metrics
The filing provides a full-year forecast for the year ending December 31, 2017, but does not contain specific historical revenue, profit, cash flow, or debt figures for the quarter ended September 30, 2017 within this text.
| Metric | Full Year 2017 Forecast |
|---|---|
| Revenues | $0 |
| Operating Loss | $12,654,000 |
| Net Loss | $12,654,000 |
| Expected Basic and Diluted Loss Per Share | $0.35 |
Note: The forecast assumes a weighted average of 35,800,000 shares. The filing does not provide specific values for cash flow, debt, or liquidity in this text.
Material Changes and Comparisons
The filing text does not provide specific historical financial data for the quarter ended September 30, 2017, nor does it provide comparative data for the prior year period to calculate material changes. It states that the Japanese report is substantially the same as the Form 10-Q for the quarter, except for the inclusion of the supplemental forecast and Japanese yen-denominated statements.
Guidance, Outlook, and Risks
- Guidance: Management forecasts zero revenue and a net loss of $12,654,000 for the full year 2017.
- Assumptions: Estimates are based on management's experience and current conditions. Independent auditors have not compiled or verified these forecasts.
- Risks and Uncertainties: Actual results may differ materially due to factors including:
- Regulatory approval timelines and outcomes for product candidates.
- Progress and results of pending clinical trials, including enrollment delays.
- Adverse side effects or inadequate therapeutic efficacy.
- Intellectual property protection and patent validity.
- Ability to raise sufficient capital or debt financing.
- Market competition and economic conditions.
- Forward-Looking Statements: The document contains numerous forward-looking statements regarding operating strategy, growth, and product development, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Verification Checklist
- Verify the actual historical financial results for the quarter ended September 30, 2017, by reviewing the referenced Form 10-Q, as this 8-K only contains the forecast.
- Confirm the company's current cash position and liquidity runway, as specific cash flow or debt figures are not provided in this text.
- Review the risk factors detailed in the Annual Report on Form 10-K for the year ended December 31, 2016, as referenced in the filing.
- Monitor the progress of clinical trials and regulatory submissions, as these are cited as primary drivers of potential variance from the forecast.
- Validate the weighted average share count of 35,800,000 used in the per-share loss calculation.